EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

Manuel Sánchez Cánovas, Javier López Robles, Evdochia Adoamnei, Diego Cacho Lavin, Carmen Diaz Pedroche, Eva Coma Salvans, Teresa Quintanar Verduguez, Francisco José García Verdejo, Mónica Cejuela Solís, Silvia García Adrián, Berta Obispo Portero, Alberto Garrido Fernández und 4 weitere

European Journal of Internal Medicine · 2024

DOI: 10.1016/j.ejim.2024.08.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Internal Medicine, 2024. Verfasst von Manuel Sánchez Cánovas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Morales Meseguer University Hospital, Murcia, Spain. Electronic address: manuelsanchezcanovas@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Protein Kinase Inhibitors, Benzimidazoles, Cyclin-Dependent Kinase 4. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sociedad Española de Oncología Médica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombosis may be included in the profile of side effects associated with CDK4/6 inhibitors. Its significance might be greater than reported in randomized clinical trials. To investigate this, a retrospective, multicenter study was conducted. The primary objective was to calculate the incidence of thrombosis associated with CDK4/6 inhibitors. Secondary objectives included examining the impact of thrombosis on survival and identifying predictor variables for the development of venous thromboembolism (VTE) or arterial thrombosis (AT). A total of 986 patients were recruited. The incidence of VTE/AT associated with CDK4/6 inhibitor treatment during the follow-up period was 5.48 %. Survival analysis did not indicate that the development of VTE/AT during CDK4/6 inhibitor treatment significantly impacted patient survival (p = 0.133). In our analysis, two variables were found to be statistically significant (p < 0.05) as predictors of VTE/AT in breast cancer patients receiving CDK4/6 inhibitor therapy. These variables were the presence of central nervous system (CNS) metastasis with an odds ratio (OR) of 3.68 (95 % CI 1.18 - 11.49) and the use of abemaciclib with an OR of 2.3 (95 % CI 1.16 - 4.57).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProtein Kinase InhibitorsBenzimidazolesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6AminopyridinesHumansFemaleRetrospective StudiesMiddle AgedSpainAgedAdultPyridinesThrombosisSurvival AnalysisIncidenceAged, 80 and overVenous ThromboembolismPiperazinesPurines

Stichwörter der Autor:innen

Breast cancerCancer-associated thrombosisCyclin-dependent kinase 4 and 6 inhibitor

Substanzen

Protein Kinase InhibitorsBenzimidazolesabemaciclibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6AminopyridinesPyridinespalbociclibribociclibCDK4 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, Morales Meseguer University Hospital, Murcia, Spain. Electronic address: manuelsanchezcanovas@gmail.com.
  • Medical Oncology Department, Morales Meseguer University Hospital, Murcia, Spain.
  • Department of Nursing, Faculty of Nursing, University of Murcia, IMIB-Arrixaca, Murcia, Spain.
  • Medical Oncology Department, Marques de Valdecilla University Hospital, IDIVAL Research Institute, Santander, Spain.
  • Internal Medicine Department, 12 de Octubre University Hospital, Madrid, Spain.
  • Oncology Continuing Care Service, Duran i Reynals - Catalan Institute of Oncology, Hospitalet de Llobregat, Spain.

Förderung

  • Sociedad Española de Oncología Médica

Zitieren

APA

Sánchez Cánovas, M., López Robles, J., Adoamnei, E., Cacho Lavin, D., Diaz Pedroche, C., Coma Salvans, E., Quintanar Verduguez, T., García Verdejo, F. J., Cejuela Solís, M., García Adrián, S., Obispo Portero, B., Garrido Fernández, A., Salvador Coloma, C., Martínez Del Prado, M. P., Mendiola, J., & Muñoz Martín, A. J. (2024). Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM). European Journal of Internal Medicine. https://doi.org/10.1016/j.ejim.2024.08.005

Vancouver

Sánchez Cánovas M, López Robles J, Adoamnei E, Cacho Lavin D, Diaz Pedroche C, Coma Salvans E, et al. Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM). European Journal of Internal Medicine. 2024. doi:10.1016/j.ejim.2024.08.005

BibTeX
@article{SnchezCnovas2024,
  author = {Sánchez Cánovas, Manuel and López Robles, Javier and Adoamnei, Evdochia and Cacho Lavin, Diego and Diaz Pedroche, Carmen and Coma Salvans, Eva and Quintanar Verduguez, Teresa and García Verdejo, Francisco José and Cejuela Solís, Mónica and García Adrián, Silvia and Obispo Portero, Berta and Garrido Fernández, Alberto and Salvador Coloma, Carmen and Martínez Del Prado, María Purificación and Mendiola, Jaime and Muñoz Martín, Andres J},
  title = {Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)},
  journal = {European Journal of Internal Medicine},
  year = {2024},
  doi = {10.1016/j.ejim.2024.08.005}
}
Kostenlos starten →